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Abstract Vesicular neurotransmitter transporters function in 
synaptic vesicles and other subcellular organeHes and they were 
thought to be involved only in neurotransmitter storage. Several 
findings have led us to test novel aspects of their function. Cells 
expressing a c-DNA coding for one of the rat monoamine trans- 
porters (VMAT1) become resistant o the neurotoxin N-methyl- 
4-phenylpyridinium (MPP ÷) [Liu et al. (1992) Cell, 70, 539-551]. 
The basis of the resistance is the VMATl-mediated transport and 
sequestration of the toxin into subcellular compartments. In addi- 
tion, the deduced sequence of VMAT1 predicts a protein that 
shows a distinct homology to a class of bacterial drug resistance 
transporters (TEXANs) that share some substrates with mam- 
malian multidrug resistance transporters (MDR) such as the P- 
gl~coprotein. These findings induced us to test whether com- 
pounds that are typically transported by MDR interact also with 
vesicular transporters. The use of ]3H]reserpine binding to deter- 
mine drug interactions with VMAT allowed assessment of the 
ability of various drugs to bind to the substrate site of the trans- 
porter. Cytotoxic compounds uch as ethidium, isometamidium, 
tetraphenylphosphonium, rhodamine, tacrine and doxorubicin, in- 
teract specifically with vesicular monoamine transporters. Vera- 
pamil, a calcium channel blocker, is also a competitive inhibitor 
of transport. In the case of rhodamine, fluorescence measure- 
ments in digitonin-permeabilized cells demonstrated ATP-de- 
pendent VMAT-mediated transport. The results imply that even 
though the bacterial and vesicular transporters are structurally 
different from the P-glycoprotein, they share a similar substrate 
range. These findings suggest a novel possible way of protection 
from the effects of toxic compounds by removal to subcellular 
compartments. 
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1. Introduction 
Fhe phenomenon of resistance of neoplastic ells and micro- 
organisms to multiple drugs has become a serious problem in 
th : treatment of tumors as well as of infections caused by 
redstant organisms [1,2]. Organisms which become cross-re- 
si~ tant to multiple drugs usually utilize membrane proteins that 
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Al'breviations." VMAT, vesicular monoamine transporter; VMAT1 and 
VMAT2 (previously known as CGAT and SVAT respectively) rat 
chromaffin granule amine transporter type 1 and 2; MPP +, N-methyl- 
4-phenylpyridinium; BMR, Bacillus-multidrug resistance; MDR, mul- 
tidrug resistance; CHO, chinese hamster ovary fibroblasts; TPP +, tetra- 
phenylphosphonium; PCA, p-chloroamphetamine. 
actively remove a wide variety of drugs from the cytoplasm, 
thus reducing their effective concentrations. The P-glycopro- 
tein, or MDR, is the archetypal member of a continuously 
growing superfamily of ABC (ATP-Binding Cassette) proteins 
[3] or Traffic ATPases [4]. The ABC proteins pump drugs 
across the cell membranes in an ATP-dependent process and 
function in many species and cell types, from bacteria to man 
[3,4]. 
Other studies describe proteins found in certain microorgan- 
isms, which, while extruding antibiotics and toxic compounds 
to the medium, are mechanistically and structurally different 
from the Traffic ATPases and define a new family which has 
been called TEXANS because of their function as Toxin 
Extruding Antiporters [5,6]. The vesicular monoamine trans- 
porters (VMAT), which remove the neurotransmitters from the 
cytoplasm into intracellular storage compartments show dis- 
tinct homology to this new family and seem to share other 
mechanistic properties [6,7]. The VMATs and other members 
of the family actively transport substrates in exchange for hy- 
drogen ions, utilizing thereby proton electrochemical gradients 
across membranes, rather than ATP [6-10]. 
VMATs are known for their substrate promiscuity. They 
transport catecholamines, indolamines, histamine, ampheta- 
mines and are inhibited by several drugs, including reserpine 
and tetrabenazine [6-10]. Reserpine is a potent antihyperten- 
sive alkaloid. Its therapeutic effect is based on its ability to 
competitively inhibit the transport of biogenic amines mediated 
by VMAT. Reserpine binds to the transporter with an ex- 
tremely high affinity and dissociates very slowly, if at all [11,12]. 
Reserpine also interacts with both, MDR [13] and Bacillus- 
multidrug resistance (BMR) [14,15] albeit with affinities in the 
micromolar range. BMR-mutants with modified sensitivities to 
reserpine have been isolated and characterized [15]. The use of 
[3H]reserpine binding measurements to determine drug interac- 
tion with the vesicular monoamine transporter allowed assess- 
ment of the relative ability of various amphetamines to bind to 
the substrate site of the vesicular transporter [16]. 
Chinese hamster ovary (CHO) fibroblasts expressing a 
cDNA coding for a vesicular transporter (VMAT1) become 
resistant to the toxic effects of the neurotoxin 1-methyl-4-phen- 
ylpyridinium (MPP +) [7]. The basis of the protection is 
VMATl-mediated transport of MPP ÷ into intracellular acidic 
compartments, thus reducing its effective concentration. This 
finding, the structural similarities of VMAT and BMR and the 
fact that reserpine is a common inhibitor of VMAT, BMR and 
MDR led us to test whether VMAT shares other substrates 
with the multidrug transporters. In this work we show that a 
series of cytotoxic ompounds such as ethidium, isometamid- 
ium, tetraphenyl-phosphonium, rhodamine and doxorubicin, 
interact specifically with vesicular monoamine transporters. 
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Tacrine, a long lasting anti-Che agent and verapamil, a calcium 
channel blocker, are also competitive inhibitors of transport. 
In addition, rhodamine transport  has been detected in digitonin 
permeabilized CV-1 fibroblasts expressing either VMAT1 or 
VMAT2. The apparent affinity of ethidium and isometamidium 
to VMATI  and VMAT2 type of transporters was compared. 
2. Mater ia l s  and  methods  
2.1. Preparation of membranes 
Chromaffin granules were isolated from bovine adrenal glands by 
differential sedimentation as described [17]. Membrane vesicles were 
obtained by osmotic shock, frozen, and stored at -70°C. 
2.2, A TP-dependent transport of FH]serotonin 
Membranes were diluted to a protein concentration of approxi- 
mately 0.075 mg/ml in a prewarmed reaction mixture (200/A) contain- 
ing 0.3 M sucrose, 10 mM K-HEPES, pH 8.5, 5 mM KCI, 2.5 mM 
MgSO 4, 5 mM Na2ATP, 0.4 ~tM [3H]serotonin and the tested inhibitor 
in different concentrations. Initial rate of serotonin uptake was meas- 
ured after incubating this suspension for 10 min at 37°C as described 
[17]. Competition assays were done at the indicated concentrations of 
inhibitor, and three concentrations of [3H]serotonin, 0.05, 0.2 and 0.8 
~tM. Results were plotted according to Dixon plot (1/V vs. [I]) and 
analyzed by linear regression. 
2.3. FH]Reserp&e binding 
Membranes were diluted to a protein concentration f = 0.15 mg/ml 
in a solution as described above, in presence or absence of 5 mM 
Na2ATP. [3H]Reserpine (20 Ci/mmol) was added to a final concentra- 
tion of 1 nM. The mixture was incubated at 37°C for 10 min (when ATP 
was present), or 4 h (in the absence of ATP). At the indicated time the 
suspension was assayed as described [12], essentially a 400 pl sample 
was applied to a 3 ml column of Sephadex LH-20 (prepacked in a 
disposable syringe by centrifugation for 15 s in a clinical centrifuge), 
centrifuged for 1 min and the effluent was assayed for radioactivity. The 
assays were performed in duplicates and parallel reaction mixtures, 
containing 5 pM reserpine were used to subtract nonspecific binding 
Eth id ium 
100 
.9 
x~ 80 
60 
• ~ 20 
m 0 
0.01 
I O. 
"C 
\i, 
0.1 1 10 100 
which was typically less than 10% of the binding to membranes. All data 
presented are mean values of duplicates. 
2.4. Growth of cells, transJections and transport assays 
The protocol for functional expression of rat VMAT1 was essentially 
[18] as described by Erickson et al. [19]. CVI cells were grown in 
DMEM supplemented with 10% FCS and 2 mM glutamine in 24-well 
collagen-treated plates. The cells were infected with recombinant vac- 
cinia virus encoding bacteriophage T7 DNA polymerase [20] and after 
30 min they were transfected with 2/2g of plasmid DNA coding for 
r-VMAT1 or b-VMAT2, using 6.4/zg transfection reagent per well 
(DOTAP-Boehringer). After 18 20 h cells were rinsed with uptake 
buffer containing 110 mM potassium tartarate, 5 mM glucose, 0.2% 
BSA, 200/2M MgC12, 1 mM ascorbic acid, 10,uM pargyline and 20 mM 
PIPES at pH 7.4. Cells were permeabilized for 10 min at 37°C in uptake 
buffer containing 10 ,uM digitonin. The medium was removed and 
replaced with fresh buffer without digitonin containing 5 mM MgSO4, 
5 mM Na2ATP and the corresponding tracers and/or inhibitors as 
indicated for the specific experiments. After 10 min the reaction buffer 
was aspirated and discarded and the cells were washed with ice-cold 
uptake buffer containing 2 mM MgSO4 and no tracers. The cells were 
then collected with 1% SDS and radioactivity assessed by liquid scintil- 
lation. All data presented are mean values of 
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Fi ;. 2. Structural formula of inhibitors and substrates of vesicular monoamine transporters. The apparent affinities as determined in this work and 
in the references quoted in the body of the paper. 
In aging System. Images were automatically collected (at 30 s intervals) 
following excitation shutter opening for 2 s intervals and were stored 
to  subsequent processing. The pseudocolor images obtained were used 
fo- fluorescence measurements (average signal of four different cell 
aleas) at the indicated times. 
3. Resu l ts  
3 I. A variety of O'tOtoxic compounds interact with vesicular 
monoamine transporters 
In the present study, the ability of substrates of MDR and 
B MR to inhibit VMAT function was tested. Previously, our 
uuderstanding of solute interaction with VMAT was limited to 
measurements of transport and its driving force, ApH. In the 
st adies presented here, the ability of a variety of solutes to 
i~ teract directly with VMAT has been evaluated by measuring 
tt~eir effect on [3H]reserpine binding. Reserpine is thought o 
brad directly to the substrate site of the transporter and is, 
tt erefore, a more precise indicator of interaction with that site. 
q he strength of this approach has been shown already in a 
srudy of the interactions of various amphetamines with VMAT 
[ 6]. In the present work we find several cytotoxic ompounds 
tiLat inhibit [3H]serotonin uptake and [3H]reserpine binding to 
ti~e chromaffin granule amine transporter f om bovine adrenal. 
The toxic organic weak base ethidium is transported by 
tMR [14] and interacts also with MDR [1]. It also inhibits 
s,,rotonin transport into chromaffin granules membrane vesi- 
c ~es from bovine adrenal in a concentration-dependent manner 
(!:Zig. 1A). At this serotonin concentration (0.4/aM), half max- 
imal inhibition is observed at 3/aM ethidium. When the exper- 
ilnent was repeated at three concentrations of serotonin, analy- 
sus of the data on Dixon plots revealed a competitive inhibition 
ith an apparent Ki of 2.5/aM (not shown). Since the transport 
of serotonin is driven by a proton electrochemical gradient and 
ethidium is an hydrophobic weak base, it could potentially 
inhibit ATP-dependent transport by two mechanisms. Dissipa- 
tion of transmembrane pH gradients by nonionic diffusion of 
ethidium could remove the driving force for transport. Since 
influx of each amine molecule requires efflux of two H + ions, 
transport isparticularly sensitive to small changes in intravesic- 
ular pH. Alternatively, ethidium might interact directly with the 
substrate binding site to competitively inhibit transport. Since 
substrates for VMAT are known to compete with [3H]reserpine 
for binding, we measured the ability of ethidium to inhibit 
binding of [3H]reserpine to chromaffin granule membranes. In
Fig. 1A we see the results of such an experiment in which 
reserpine binding was assayed in the presence and in the ab- 
sence of ATE ATP is known to accelerate binding of reserpine 
by virtue of its ability to generate a proton electrochemical 
gradient via the V-ATPase. Thus, again, inhibition of [3H]reser- 
pine binding could result from competition at the reserpine 
binding site or dissipation of ApH. By measuring binding rates 
in the presence and absence of ATP, we were able to distinguish 
between these two mechanisms. Half maximal inhibition of 
[3H]reserpine binding occurred at 5 /aM ethidium, whether 
ATP-dependent or -independent binding was measured and 
this is practically identical to the concentration which inhibits 
serotonin transport. The findings unequivocally demonstrate 
that ethidium exerts its inhibitory effect as a competitive inhib- 
itor of the transporter rather than through an effect on the 
A/-~H + . 
For comparison, the mode of action of a weak base such as 
p-chloroamphetamine (PCA) is described in Fig. 1B. This sym- 
pathomimetic amine, inhibits serotonin transport through dis- 
sipation &Aft,+ (K0.5 of 1/aM and see also [16]). PCA has no 
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3 3 Fig. 3. Inhibition of chromaffin granule [ H]serotonin transport and [ H]reserpine binding by MDR substrates. The effect of the indicated compounds 
on ATP dependent transport of [3H]serotonin (..) and [3H]reserpine binding in the presence (e) or in the absence (0) of ATP was tested to assess 
their ability to interact with the vesicular monoamine transporter from bovine adrenal chromaffin granules. 
significant effect on reserpine binding to the transporter meas- 
ured in the absence of ATP (up to 800 pM of the drug). As 
expected from an agent collapsing AfiH+, PCA inhibits the rate 
of ATP-dependent reserpine binding at intermediate concentra- 
tions, (K0.5 = 120 pM) since this reaction is less sensitive to 
changes in ApH than transport [12,16]. Although not evident 
from the figure, the binding rates are inhibited to the levels in 
the absence of ATE 
Using the experimental paradigm described the effect of the 
following substrates or 'modulators' of multidrug transporters 
has been tested (structural formulas in Fig. 2): Verapamil is 
a calcium-channel blocker [21]. Tetraphenylphosphonium 
(TPP÷), a lipophylic ation, is widely used for measuring mem- 
brane potential [22]. Doxorubicin is an antineoplastic agent 
[21]. Isometamidium is an antitrypanosomal agent hus far un- 
tested in other multidrug transporters [23]. Tacrine, is a long 
lasting anti-Che agent [24]. All were shown to be inhibitors of 
serotonin transport and reserpine binding (Fig. 3). The most 
potent inhibitor was isometamidium, which inhibited all reac- 
tions with a K0.5 of 0.25 pM for the three reactions tested. 
Verapamil inhibited with a K05 of 7.5 /IM, while TPP + and 
Doxorubicin were relatively poor inhibitors. TPP ÷ inhibits se- 
rotonin transport with a K0.5 of about 80 pM. TPP+ is the only 
inhibitor in which the charge is in a phosphonium oiety rather 
than in the classical amine. Therefore a Dixon plot analysis was 
carried out to confirm the competitive nature of the inhibition 
by the latter and the apparent Ki calculated was 50/.tM (not 
shown); inhibition of reserpine binding required slightly higher 
concentrations of the cation. 
Some compounds with no effect on transport were also 
screened: Vincristine is an antineoplastic agent, substrate of 
MDR [1] (Fig. 3). Norfloxacin is an antibacterial nalog of 
nalidixic acid and is the classical substrate of BMR [14]. Para- 
quat is an herbicide structurally related to the neurotoxin 
MPP +. Acetylcholine is structurally unrelated but it is a sub- 
strate of the highly similar vesicular acetylcholine transporter 
(VACHT). None of the above mentioned compounds had any 
effect on serotonin transport up to concentrations of 200 pM 
(only the results for vincristine are shown in Fig. 3 as an exam- 
ple, the rest of the data are not shown). 
Two distinct types of VMAT's have been characterized: 
VMAT1 and VMAT2 type [7]. The two transporters are highly 
similar, coded by genes in different chromosomes and have 
been shown to differ in some of their pharmacological proper- 
ties [25]. We compared the potency of ethidium and isomet- 
amidium on the two transporter types transiently expressed in
CV1 cells. Both inhibit VMAT2 with a slightly higher potency 
than VMAT1 (Fig. 4). The ICs0 values are respectively 4.5 and 
0.1 pM for VMAT2 and 10 and 0.3 pM for VMAT1. 
3.2. Rhodamine 6G is actively transported by both VMAT1 and 
VMAT2 
Competitive inhibition suggests interaction at the substrate 
site of the transporter. However, not all the drugs interacting 
at the recognition site are necessarily transported. Thus, while 
dopamine, adrenaline, noradrenaline, serotonin, fenfluramine, 
MPP ÷, MBIG are substrates of VMAT, reserpine is not trans- 
ported even though it shows the highest affinity for the binding 
site. Assaying transport of hydrophobic substrates implies 
problems related with their high passive leaks and non-specific 
binding. Therefore we selected a substrate which can be easily 
monitored on-line by measuring fluorescence l vels on single 
cells. Rhodamine 6G was tested first for inhibitor of [3H]sero- 
tonin transport and [3H]reserpine binding as described above 
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Fi~:. 4. Inhibition of r-VMAT1 and b-VMAT2 [3H]serotonin transport by ethidium, and isometamidium. The effect of ethidium and isornetamidium 
on ATP dependent transport of [3H]serotonin was tested in CV1 cells transfected with the appropriate clones as described in section 2. 
a1~d found to inhibit both with an IC50 of 5 pM (Fig. 5A). 
R hodamine 123 and 6G are used as mitochondrial markers and 
they accumulate in these organelles in an energy dependent 
manner [26]. Permeabilization f the cell by digitonin causes 
depletion of the energy sources as detected by the fact that 
VMAT-mediated transport into subcellular organelles depend- 
en t on extemally added ATP [18,19]. Mitochondria of digitonin 
pcrmeabilized CV-1 cells do not significantly accumulate 
R hodamine (Fig. 5B). However when either VMAT or VMAT2 
are expressed in these cells, a rapid accumulation is observed, 
a~d this process is inhibited by reserpine (5 pM) (not shown). 
4. Discuss ion 
4. t. Vesicular monoamine transporters show a high substrate 
promiscuity similar to multidrug transporters 
In this work an interaction of vesicular monoamine trans- 
p, wters with a wide variety of compounds has been demon- 
st "ated: ethidium, isometamidium, doxorubicin, tacrine, 
rhodamine, tetraphenylphosphonium andverapamil (Fig. 2). 
Other drugs recognized by VMATs in addition to adrenaline, 
n,,radrenaline, dopamine and serotonin include histamine [25], 
the neurotoxin MPP ÷ [7,27-29]; fenfluramine, the sympatho- 
mimetic amines and 3,4-methylenedioxy-methamphetamine 
(MDMA, also known as 'ecstasy') [16], and meta-iodoben- 
z} lguanidine [30], an adrenal imaging agent used for the scinti- 
g~aphic detection of human pheochromocytoma. A group of 
in hibitors that seem to act on a site different from the substrate 
siLe and represented by tetrabenazine, ketanserine and related 
c~,mpounds [31] has not been included in the figure. 
Interestingly, most of the compounds above mentioned have 
been reported to interact with other multidrug transporters 
suggesting that there is a marked overlap in substrate specificity 
in the various multidrug transporters. This may suggest a pos- 
sible common solution to the problem of polyspecificity with 
several minor modifications. This polyspecificity appeared ur- 
ing evolution in five different families: in ABC type, TEXANs, 
Mini Texans, RND and the kidney organic ation transporter. 
This may hint at a common need of primitive living cells for 
mechanisms of protection from an unfriendly environment. 
Later on in evolution some of the multidrug transporters which 
evolved have specialized to given functions uch as neurotrans- 
mitter transport, phospholipid translocation and others. 
An interesting question is how these proteins can recognize 
with high affinity such a broad array of substrates. One such 
system which copes with this type of problem and has been 
studied at the atomic level are the Major Histocompatibility 
Complex (MHC) molecules [32,33]. The conclusion from these 
studies is that the MHC molecules can bind a variety of pep- 
tides because they interact with a few structural elements com- 
mon to all peptides. Binding occurs with high affinity primarily 
because of extensive interaction with the peptide backbone and 
with the amino and carboxy termini of the peptide. The side 
chains that differ from peptide to peptide have little if any 
effect. A parallel, although mechanistically different situation 
occurs in cholinesterases, many of which interact with a wide 
array of asymmetric ligands with a cholinium moiety at one end 
and a charged acyl moiety at the other. The interaction is 
mediated through the primary attraction to negatively charged 
surface residues and subsequent hydrophobic nteractions [34]. 
We speculate that similar principles are utilized by polyspeci- 
fic transporters. A few generalizations can be tentatively drawn 
based on our studies on VMAT. All the effective known sub- 
strates and inhibitors of VMAT contain an aromatic ring and 
a positive charge, and therefore we can suggest that these are 
involved in the interaction (Fig. 2). In a given series of corn- 
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pounds, hydroxyl, methoxy, or amino substitutents in the ring, 
improve the affinity of the substrates [8-10,16]. Introduction of 
a negative charge in the molecule greatly diminishes the affinity 
of interaction (see here norfloxacin and also [35,37] for deriva- 
tives of reserpine and fluoroserotonin). The only known inhib- 
itor with a positive charge other than ammonium, is TPP ÷, 
which displays a relatively low affinity (K~ = 50/.tM). The inter- 
action therefore seems to be mediated through a primary low 
affinity attraction to positively charged residues and subse- 
quent more specific hydrophobic interactions with a properly 
substituted aromatic ring. 
Many of the compounds described in Fig. 2 have also been 
documented as substrates of VMATs: mlBG [30], the neuro- 
toxin MPP ÷ [7,27-29] and Rhodamine 6G (this work). To as- 
sess whether any of the other compounds described here as 
inhibitors are also substrates and to test VMATs possible roles 
in conferring resistance to the toxic effect he resistance of CHO 
fibroblasts expressing VMAT has been compared to that of a 
non-expressing line [7]. The following compounds were tested: 
ethidium, isometa-midium and doxorubicin. Only marginal dif- 
ferences in resistance were observed in all cases (data not 
shown). In both cell lines reserpine dramatically increased the 
sensitivity to all the toxic compounds even though it was not 
toxic by itself. These observations are in agreement with find- 
ings that CHO cells have a high level of expression of an 
MDR-type protein with a specificity very similar to VMAT. In 
this cell line MPP ÷ is the only toxic substrate specific to VMAT 
found thus far. 
It is not known yet whether mammalian TEXANs play in 
living organisms any role other than transport of neurotrans- 
mitters. In microorganisms, the TEXANs have been identified 
based on their ability to confer resistance against antibiotics 
and other toxic compounds. The results presented in this report 
suggest hat VMAT are multidrug transporters. This follows 
demonstration that VMATs can protect CHO fibroblasts from 
the toxicity ofa cytotoxic agent, such as MPP ~ [7]. We can now 
only speculate about a possible role of these proteins and other 
TEXANs in the intact organism as another novel way of detox- 
ification at the cellular level by compartmentalization. 
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